Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$18.18 USD

18.18
518,695

+0.20 (1.11%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

Myriad Genetics' Test Added in Disease Activity Measure List

Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

Myriad Genetics Presents New Test Data in Autoimmune Segment

Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.

Company News For Nov 6, 2019

Companies In The News Are: CPE, EVER, MYGN, AAN

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

Myriad Genetics (MYGN) Q1 Earnings and Revenues Miss Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -75.76% and -8.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod

Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.

Myriad (MYGN) Up 5.9% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up

Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.

Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?

Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.

What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?

Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.

Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics Divests NAMIC Portfolio to Medline Industries

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

Myriad Genetics Announces Study Results Of myRisk Cancer Test

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

Myriad Genetics' (MYGN) POLO Study Shows Positive Results

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

Why Should You Hold on to Myriad Genetics (MYGN) Stock?

Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

Myriad Genetics (MYGN) Beats Q3 Earnings Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck

The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.

Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake

The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.